GlaxoSmithKline (GSK) is buying cancer biotech firm Tesaro for for $5.1 billion; Republicans in Congree are giving up efforts to cut Planned Parenthood funding; Medicare is using financial incentives to reward or punish nursing homes based on how often their residents ended up back in hospitals within 30 days of discharge.
GlaxoSmithKline is buying cancer biotech firm Tesaro for for $5.1 billion, STAT reported. Tesaro’s ovarian cancer drug Zejula belongs to a class of cancer drugs called poly (ADP-ribose) polymerase (PARP) inhibitors. Zejula sales are expected to be in range of $233 million to $238 million this year. GlaxoSmithKline said the purchase “will strengthen our pharmaceuticals business by accelerating the build of our oncology pipeline and commercial footprint.” Biotech mergers and acquisitions have been generally lackluster this year, so the deal may spark renewed optimism for new deals in 2019.
With Democrats preparing to take control of the House, Congressional Republicans are giving up on years of promises to cut federal funding for Planned Parenthood, Politico reported. That became evident last week when Senator Ted Cruz, R-Texas, briefly tried and failed to push through one last bid to push through Planned Parenthood cuts, a repeal of the Affordable Care Act, and other conservative priorities. But rattled by the possibility of a shutdown next week triggered by President Donald Trump’s border wall demands, most Republicans, dismissed his bid, infuriating anti-abortion groups, who plan to turn to state legislatures and the courts.
The United States is using financial incentives to reward or punish nursing homes based on how often their residents ended up back in hospitals within 30 days of leaving, Kaiser Health News reported. The new Medicare program is altering a year’s worth of payments to 14,959 skilled nursing facilities. It lowered payments to nearly 11,000 nursing homes and gave bonuses to nearly 4000 others. These bonuses and penalties are also intended to discourage nursing homes from discharging patients too quickly. Hospitalizations of nursing home residents, while decreasing in recent years, remain a problem, with nearly 11% of patients in 2016 being sent to hospitals for conditions that might have been averted with better medical oversight.
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage
April 4th 2025This study examined postdiagnosis breast cancer treatment outcomes for Medicare Advantage vs fee-for-service (FFS) Medicare in Ohio and found no significant differences overall but disparities for Black patients with FFS Medicare.
Read More